BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35190177)

  • 21. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
    Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
    Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
    Mitsudomi T; Ito H; Okada M; Sugawara S; Shio Y; Tomii K; Okami J; Sakakura N; Kubota K; Takamochi K; Atagi S; Tsuboi M; Oizumi S; Ikeda N; Ohde Y; Ntambwe I; Mahmood J; Cai J; Tanaka F
    Cancer Sci; 2024 Feb; 115(2):540-554. PubMed ID: 38098261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
    Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option.
    Faehling M; Fallscheer S; Kramberg S; Sträter J; Eschmann S; Sätzler R; Heinzelmann F
    Eur J Cancer; 2021 Oct; 156():175-186. PubMed ID: 34461420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
    Paz-Ares LG; Ramalingam SS; Ciuleanu TE; Lee JS; Urban L; Caro RB; Park K; Sakai H; Ohe Y; Nishio M; Audigier-Valette C; Burgers JA; Pluzanski A; Sangha R; Gallardo C; Takeda M; Linardou H; Lupinacci L; Lee KH; Caserta C; Provencio M; Carcereny E; Otterson GA; Schenker M; Zurawski B; Alexandru A; Vergnenegre A; Raimbourg J; Feeney K; Kim SW; Borghaei H; O'Byrne KJ; Hellmann MD; Memaj A; Nathan FE; Bushong J; Tran P; Brahmer JR; Reck M
    J Thorac Oncol; 2022 Feb; 17(2):289-308. PubMed ID: 34648948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
    Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
    Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.
    Savic M; Kontic M; Ercegovac M; Stojsic J; Bascarevic S; Moskovljevic D; Kostic M; Vesovic R; Popevic S; Laban M; Markovic J; Jovanovic D
    Thorac Cancer; 2017 Sep; 8(5):393-401. PubMed ID: 28671758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
    Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS
    N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
    Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer.
    Liveringhouse CL; Latifi K; Asous AG; Lam NB; Rosenberg SA; Dilling TJ; MacMillan GV; Chiappori AA; Haura EB; Creelan B; Gray JE; Tanvetyanon T; Shafique MR; Saltos AN; Weiner AA; Clarke J; Kelsey CR; Kim S; Caudell JJ; Rose TA; Conejo-Garcia JR; Li J; Schell MJ; Antonia SJ; Perez BA
    Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):837-848. PubMed ID: 36657497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Application of Neoadjuvant Immuno-chemotherapy in NSCLC].
    Chen S; Zhao Z; Long H
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):284-292. PubMed ID: 33910277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
    Imai H; Kijima T; Azuma K; Kishi K; Saito H; Yamaguchi T; Tanizaki J; Yoneshima Y; Fujita K; Watanabe S; Kitazono S; Fukuhara T; Hataji O; Toi Y; Mizutani H; Hamakawa Y; Maemondo M; Ohsugi T; Suzuki K; Horinouchi H; Ohe Y
    Jpn J Clin Oncol; 2024 Apr; 54(4):452-462. PubMed ID: 38271158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
    Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L
    N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
    Versluis JM; Menzies AM; Sikorska K; Rozeman EA; Saw RPM; van Houdt WJ; Eriksson H; Klop WMC; Ch'ng S; van Thienen JV; Mallo H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; van der Wal A; Bruining A; van de Wiel BA; Scolyer RA; Haanen JBAG; Schumacher TN; van Akkooi ACJ; Long GV; Blank CU
    Ann Oncol; 2023 Apr; 34(4):420-430. PubMed ID: 36681299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Ipilimumab + Nivolumab + Chemotherapy Enhances Pathologic Responses.
    Cancer Discov; 2023 Jun; 13(6):OF11. PubMed ID: 36999975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
    Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
    BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
    Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
    Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
    Provencio M; Nadal E; González-Larriba JL; Martínez-Martí A; Bernabé R; Bosch-Barrera J; Casal-Rubio J; Calvo V; Insa A; Ponce S; Reguart N; de Castro J; Mosquera J; Cobo M; Aguilar A; López Vivanco G; Camps C; López-Castro R; Morán T; Barneto I; Rodríguez-Abreu D; Serna-Blasco R; Benítez R; Aguado de la Rosa C; Palmero R; Hernando-Trancho F; Martín-López J; Cruz-Bermúdez A; Massuti B; Romero A
    N Engl J Med; 2023 Aug; 389(6):504-513. PubMed ID: 37379158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors.
    Bott MJ; Cools-Lartigue J; Tan KS; Dycoco J; Bains MS; Downey RJ; Huang J; Isbell JM; Molena D; Park BJ; Rusch VW; Sihag S; Jones DR; Adusumilli PS
    Ann Thorac Surg; 2018 Jul; 106(1):178-183. PubMed ID: 29550207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.